Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

Completed · Phase 2

Conditions studied: Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), Tauopathies

In brief

The study will investigate the ability of a new PET tracer, 18F-AV-1451, to detect depositions of a protein, called tau, in the brains of people with a mutation in the tau gene that causes deposition of the protein, and in people without the mutation. Up to three 18F-AV-1451 scans will be performed (one per year) on control subjects without MAPT mutations, presymptomatic mutation carriers, and symptomatic mutation carriers.

Key facts

Study ID

NCT02676843

Run by

Columbia University

People needed

7

Starts

2016-04-01

Expected to finish

2018-11-25

Last updated by the study team

2019-12-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Members of families with established MAPT mutations, who either have the capacity to consent to participate in the protocol, or else have designated a surrogate/proxy to consent to participate in this study

You may not qualify if…

• Unwillingness to participate
• Usage of medication which significantly prolongs QT interval
• Pregnancy or plans for pregnancy within 90 days after participating in study

Where it is running

• Morton A. Kreitchman PET Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.